ERBB2 and neoplasm: Taking into consideration the response rates, patients whose tumours had high Ki67 expression levels or HER2 amplification presented the highest rates of response to primary chemotherapy (for Ki67, a significant association was found with both clinical and pathological responses; for HER2, a significant association was surprisingly observed with clinical response only) (see Table 3).